Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.03 USD | -0.96% | -1.91% | -49.76% |
05:37pm | Ainos to Start Clinical Trial of Potential Animal Drug for Oral Disease Treatment | MT |
13/05 | Earnings Flash (AIMD) AINOS Reports Q1 Revenue $20,729 | MT |
Business Summary
Number of employees: 46
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Point-of-care Testing
100.0
%
| 4 | 100.0 % | 0 | 100.0 % | -96.53% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 4 | 100.0 % | 0 | 100.0 % | -96.53% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chun Hsien Tsai
CEO | Chief Executive Officer | 54 | 15/21/15 |
Lawrence Lin
COO | Chief Operating Officer | 55 | 01/21/01 |
Shu Ying Pan
SAM | Sales & Marketing | - | - |
Chih-Heng Lu
PRN | Corporate Officer/Principal | 44 | 11/21/11 |
Junyong Lee
LAW | General Counsel | 54 | 01/21/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Yao Chung Chiang
BRD | Director/Board Member | 70 | 15/21/15 |
Pao Sheng Wei
BRD | Director/Board Member | 66 | 15/22/15 |
Chung Yi Tsai
BRD | Director/Board Member | 47 | 15/21/15 |
Chung Jung Tsai
BRD | Director/Board Member | 52 | 15/21/15 |
Ting Chuan Lee
BRD | Director/Board Member | 40 | 15/21/15 |
Wen Han Chang
BRD | Director/Board Member | 60 | 15/21/15 |
Chun Hsien Tsai
CEO | Chief Executive Officer | 54 | 15/21/15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 6,144,506 | 2,857,736 ( 46.51 %) | 0 | 46.51 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-49.76% | 6.39M | |
+7.23% | 111B | |
+10.13% | 106B | |
-12.34% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-9.14% | 16.81B | |
+37.92% | 12.54B | |
-24.95% | 8.09B |
- Stock Market
- Equities
- AIMD Stock
- Company Ainos, Inc.